Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I4/254

[1] Noskin G A, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci[J]. Antimicrob Agents Chemother, 1999, 43(8): 2059-2062.
[2] Ozkaya-Parlakay A, Kara A, Celik M, et al. Early lactic acidosis associated with linezolid therapy in paediatric patients[J]. Int J Antimicrob Agents, 2014, 44(4): 334-336.
[3] Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy[J]. Clin Infect Dis, 2002, 34(5): 695-698.
[4] Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia[J]. Int J Antimicrob Agents. 2009, 33(1): 98-99.
[5] Gerson S L, Kaplan S L, Bruss J B, et al. Hematologic effects of linezolid: summary of clinical experience[J]. Antimicrob Agents Chemother, 2002, 46(8): 2723-2726.
[6] Antal E J, Hendershot P E, Batts D H, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine[J]. J Clin Pharmacol, 2001, 41(5): 552-562.
[7] Lin Y H, Wu V C, Tsai I J, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency[J]. Int J Antimicrob Agents, 2006, 28(4): 345-351.
[8] Wu V C, Wang Y T, Wang C Y, et al. High frequency of thrombocytopenia and anemia among patients with end-stage renal disease[J]. Clin Infect Dis, 2006, 42(1):66-72
[9] 董海燕, 邹雅敏, 董亚琳, 等. Logistic模型和ROC曲线对利奈唑胺致血小板减少症的预测分析[J]. 中国医院药学杂志, 2013(22): 1827-1831.
[10] Soriano A, Ortega M, Garcia S, et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse eveents induced by linezolid[J]. Antimicrob Afents Chemother, 2007, 51(7):2559-2663.
[11] Matsumoto K, Takeshita A, Ikawak, et al. Higer linezolid exposure and higher frequency of thrombocytopeniain patients with renal dysfunction[J]. Int J Antimicrob Agents, 2010, 36(2):179-181.
[12] Grau S, Morales-Molina J A, Mateude Antonio J, et al. Linezolid:low pretreatment platelet values could increase the risk of thrombocytopenia[J]. J Antimicro Chemother, 2005 56(2):440-1.
[13] Hiraki Y, Tsuji Y, Matsumoto K, et al. Influence of Linezolid Clearance on the Induction of Thromobocytopenia and Reduction of Hemoglobin[J]. Am J Med Sci, 2011, 342(6):456-460.
[14] Niwa T, Suzuki A, Sakakibara S, et al. Reftrospective cohort chart review study of fafctorsassociated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy[J]. Cli Ther, 2009, 31(10):2126-2133.
[15] Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients[J]. Antimicrob Agents Chemother, 2011,55(5):1867-186173.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.